SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)
Website: www.sbpgroup.com
(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
DATA FROM PHASE I CLINICAL STUDY OF TQB6411 "EGFR/C-MET ADC" PRESENTED AT 2026 ASCO

The board of directors (the "**Board**") of Sino Biopharmaceutical Limited (the "**Company**", together with its subsidiaries, the "**Group**") announces that the data from a Phase I first-in-human study of TQB6411 "EGFR/c-Met ADC", an investigational national Category 1 innovative drug independently developed by the Group's subsidiary, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. ("**CTTQ**"), in patients with advanced solid tumours, was presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

As of 31 December 2025, a total of 26 patients were enrolled in this study (NCT07043751), with a median age of 60 (ranging from 33 to 75 years old), of whom 46.2% were female. All enrolled patients had advanced malignant tumours that had failed or were intolerant to standard-of-care therapy, including non-small cell lung cancer (NSCLC; n=21), esophageal cancer (n=3) and colorectal cancer (n=2). All patients had received at least one prior line of systemic therapy.

As of 13 January 2026, doses had been escalated from the initial level of 0.8 mg/kg to 6.6 mg/kg across five dose levels, with no dose-limiting toxicities (DLTs) observed. In the ≥4 mg/kg dose groups, among 9 patients who underwent at least one imaging assessment, 4 patients achieved partial response (PR), resulting in an objective response rate (ORR) of 44.4% and a disease control rate (DCR) of 100%. In particular, in the 5.3 mg/kg group, one NSCLC patient who had received two prior lines of therapy achieved a 55.2% reduction from baseline in targeted lesions; in the 4.0 mg/kg group, two NSCLC patients who had received three or more prior lines of therapy achieved reductions of 30.4% and 48.1% in targeted lesions, respectively, demonstrating robust anti-tumor activity in heavily pretreated patients with advanced tumours. In terms of safety, among 23 patients with at least 21 days of follow-up, the incidence of Grade 3 treatment-related adverse event (TRAEs) was 21.7%, and no Grade≥4 TRAEs were observed across the overall population. In respect of the pulmonary toxicity, no interstitial lung disease (ILD) was reported during the study.

The study demonstrated that TQB6411 has a favourable safety profile at effective doses, particularly in terms of its low haematological toxicity. TQB6411 exhibits a stronger binding affinity for c-Met than for EGFR, with a potency ratio of 1:2. Such characteristic enhances the killing effect of TQB6411 on tumour cells with high c-Met expression, while mitigating EGFR-mediated adverse events, such as skin toxicity.

The overexpression of the epidermal growth factor receptor (EGFR) and the hepatocyte growth factor receptor (c-Met) is common in various solid tumours, including NSCLC, esophageal cancer, and colorectal cancer. Upon EGFR pathway blockade, tumour cells often switch to activate the c-Met pathway to bypass inhibition. Such mechanism is widely recognised as one of the core drivers of resistance to existing EGFR-targeted therapies.

As one of the first EGFR/c-Met ADCs worldwide to report clinical data, TQB6411 leverages a well-established target combination and a c-Met biased affinity design, thereby reducing development risks while establishing a differentiated competitive edge. The Phase I data presented demonstrates tumour regression at low doses in heavily pretreated patients with advanced tumours, accompanied by a favourable safety profile. Based on the abovementioned, the Group is expediting the clinical development of this drug.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 1 June 2026

As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.